BRIEF—ICER draft report on opioid use disorder drugs

The USA’s Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of medications for addiction treatment (MAT) used for individuals with opioid use disorder.

The draft report will be open to public comment until 5pm ET on October 4, 2018.

The ICER’s report assesses the effectiveness and value of a buprenorphine implant (Probuphine, from Titan Pharmaceuticals), an extended-release naltrexone injection (Vivitrol, from Alkermes), and two extended-release buprenorphine injections: Sublocade (from Indivior) and CAM2038 (from Braeburn), an investigational agent currently under FDA review.

The report will be subject to deliberation during a public meeting of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees, on November 8, 2018.

The ICER will review all comments and incorporate any necessary changes in the Evidence Report and Revised Voting Questions that will be posted on or about October 25, 2018.

All comments and ICER’s response to comments will be posted publicly along with the Evidence Report.